https://doi.org/10.4081/monaldi.2023.2619
Classification of COPD as ABCD according to GOLD 2011 and 2017 versions in COPD patients at University Medical Center in Ho Chi Minh City, Vietnam
Submitted: April 28, 2023
Accepted: June 21, 2023
Published: July 28, 2023
Accepted: June 21, 2023
Abstract Views: 570
PDF_early view: 274
Supplementary: 61
Supplementary: 61
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
In 2017, Global Initiative for Chronic Lung Disease (GOLD) made substantial changes to its ABCD group categorization. Although several studies had been conducted to assess the impact of the new GOLD category, there was no research on the change of the GOLD classification in Vietnam. This retrospective analysis was conducted at Asthma and COPD clinic at the University Medical Center in Ho Chi Minh City, Vietnam. Our study population comprised patients visiting Medical Center from January 2018 to January 2020. We categorized patients’ demographic, clinical characteristics and pharmacotherapy based on GOLD 2011 and 2017 guidelines. A comparison between the two versions was also determined. A total of 457 patients were included in this study. The percentage of groups A, B, C and D according to GOLD 2011 was 5%, 20.8%, 13.1% and 61.1%; and according to GOLD 2017 was 6.1%, 34.1%, 12% and 47.8%, respectively. In terms of gender, male patients constituted nearly 95% of the study’s population (433/457 patients). Regarding pharmacotherapy, approximately 20% of the low-risk group (group A-B) was overtreated with ICS components: LABA+ICS (15.8%) and LAMA+LABA+ICS (3.8%). There were 13.3% and 1.1% of patients transferred from D to B and from C to A, respectively. All of them had lower FVC% pred, FEV1% pred and FEV1/FVC than the patients remained in group B or A (p<0.005). This is the first research in Vietnam to show the distribution of COPD patients using both the GOLD 2011 and GOLD 2017 criteria. There was 14% of patients reclassified from high-risk groups to low-risk groups when changing from 2011 to 2017 version and discordance of medications between guidelines and real-life practice. Therefore, clinicians should use their clinical competence to consider patients' conditions before deciding the appropriate therapeutic approach. Consequently, further studies were required to evaluate the effect of the change in GOLD classification.
Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. GOLD executive summary. Am J Resp Crit Care 2017;195:557-82.
DOI: https://doi.org/10.1164/rccm.201701-0218PP
Safiri S, Carson-Chahhoud K, Noori M, et al. Burden of chronic obstructive pulmonary disease and its attributable risk factors in 204 countries and territories, 1990-2019: results from the Global Burden of Disease Study 2019. BMJ 2022;378:e069679.
DOI: https://doi.org/10.1136/bmj-2021-069679
Rodriguez-Roisin R, Rabe KF, Vestbo J, et al. Global Initiative for Chronic Obstructive Lung Disease (GOLD) 20th anniversary: a brief history of time. Eur Respir J 2017;50:1700671.
DOI: https://doi.org/10.1183/13993003.00671-2017
Vestbo J, Hurd SS, Agustí AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Resp Crit Care 2013;187:347-65.
DOI: https://doi.org/10.1164/rccm.201204-0596PP
Agustí A, Celli BR, Criner GJ, et al. Global initiative for chronic obstructive lung disease 2023 report: GOLD executive summary. Am J Resp Crit Care 2023;207:819-37.
DOI: https://doi.org/10.1164/rccm.202301-0106PP
Cabrera López C, Casanova Macario C, Marín Trigo JM, et al. Comparison of the 2017 and 2015 global initiative for chronic obstructive lung disease reports. Impact on grouping and outcomes. Am J Resp Crit Care 2018;197:463-9.
DOI: https://doi.org/10.1164/rccm.201707-1363OC
Sun L, Chen Y, Wu R, et al. Changes in definition lead to changes in the clinical characteristics across COPD categories according to GOLD 2017: a national cross-sectional survey in China. Int J Chron Obstruct Pulmon Dis 2017;12:3095-102.
DOI: https://doi.org/10.2147/COPD.S142801
Gayle A, Dickinson S, Morris K, et al. What is the impact of GOLD 2017 recommendations in primary care?–a descriptive study of patient classifications, treatment burden and costs. Int J Chron Obstruct Pulmon Dis 2018;13:3899-900.
DOI: https://doi.org/10.2147/COPD.S194746
Cui Y, Dai Z, Luo L, et al. Classification and treatment of chronic obstructive pulmonary disease outpatients in China according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017: comparison with GOLD 2014. J Thorac Dis 2019;11:1303-15.
DOI: https://doi.org/10.21037/jtd.2019.03.99
Hsieh M-J, Huang S-Y, Yang T-M, et al. The impact of 2011 and 2017 Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD) guidelines on allocation and pharmacological management of patients with COPD in Taiwan: Taiwan Obstructive Lung Disease (TOLD) study. Int J Chron Obstruct Pulmon Dis 2018;13:2949-59.
DOI: https://doi.org/10.2147/COPD.S176065
Oishi K, Hirano T, Hamada K, et al. Characteristics of 2017 GOLD COPD group A: A multicenter cross-sectional CAP study in Japan. Int J Chron Obstruct Pulmon Dis 2018:3901-7.
DOI: https://doi.org/10.2147/COPD.S181938
Song JH, Lee C-H, Um S-J, et al. Clinical impacts of the classification by 2017 GOLD guideline comparing previous ones on outcomes of COPD in real-world cohorts. Int J Chron Obstruct Pulmon Dis 2018:3473-84.
DOI: https://doi.org/10.2147/COPD.S177238
Marçôa R, Rodrigues DM, Dias M, et al. Classification of chronic obstructive pulmonary disease (COPD) according to the new Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017: comparison with GOLD 2011. COPD 2018;15:21-6.
DOI: https://doi.org/10.1080/15412555.2017.1394285
Kahnert K, Alter P, Young D, et al. The revised GOLD 2017 COPD categorization in relation to comorbidities. Respir Med 2018;134:79-85.
DOI: https://doi.org/10.1016/j.rmed.2017.12.003
Högman M, Sulku J, Ställberg B, et al. 2017 Global Initiative for Chronic Obstructive Lung Disease reclassifies half of COPD subjects to lower risk group. Int J Chron Obstruct Pulmon Dis 2018;13:165-73.
DOI: https://doi.org/10.2147/COPD.S151016
Smid DE, Spruit MA, Houben-Wilke S, et al. Burden of COPD in patients treated in different care settings in the Netherlands. Respir Med 2016;118:76-83.
DOI: https://doi.org/10.1016/j.rmed.2016.07.015
Nguyen HT, Collins PF, Pavey TG, et al. Nutritional status, dietary intake, and health-related quality of life in outpatients with COPD. Int J Chron Obstruct Pulmon Dis 2019:215-26.
DOI: https://doi.org/10.2147/COPD.S181322
Duong-Quy S, Tran Van H, Vo Thi Kim A, et al. Clinical and functional characteristics of subjects with asthma, COPD, and asthma-COPD overlap: a multicentre study in Vietnam. Can Respir J 2018;2018:1732946.
DOI: https://doi.org/10.1155/2018/1732946
Nguyen T-S, Nguyen TLH, Van Pham TT, et al. Impact of pharmaceutical care in the improvement of medication adherence and quality of life for COPD patients in Vietnam. Respir Med 2019;153:31-7.
DOI: https://doi.org/10.1016/j.rmed.2019.05.006
Kobayashi S, Hanagama M, Ishida M, et al. Clinical characteristics and outcomes in Japanese patients with COPD according to the 2017 GOLD classification: the Ishinomaki COPD Network Registry. Int J Chron Obstruct Pulmon Dis 2018;13:3947-55.
DOI: https://doi.org/10.2147/COPD.S182905
Brandsma CA, Van den Berge M, Hackett TL, et al. Recent advances in chronic obstructive pulmonary disease pathogenesis: from disease mechanisms to precision medicine. J Pathol 2020;250:624-35.
DOI: https://doi.org/10.1002/path.5364
Hikichi M, Mizumura K, Maruoka S, et al. Pathogenesis of chronic obstructive pulmonary disease (COPD) induced by cigarette smoke. J Thorac Dis 2019;11:S2129-S40.
DOI: https://doi.org/10.21037/jtd.2019.10.43
Lange P, Ahmed E, Lahmar ZM, et al. Natural history and mechanisms of COPD. Respirology 2021;26:298-321.
DOI: https://doi.org/10.1111/resp.14007
Singh D, Agusti A, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease: the GOLD science committee report 2019. Eur Respir J 2019;53:1900164.
DOI: https://doi.org/10.1183/13993003.00164-2019
Ntritsos G, Franek J, Belbasis L, et al. Gender-specific estimates of COPD prevalence: a systematic review and meta-analysis. Int J Chron Obstruct Pulmon Dis 2018;13:1507-14.
DOI: https://doi.org/10.2147/COPD.S146390
Zhang H, Wu F, Yi H, et al. Gender differences in chronic obstructive pulmonary disease symptom clusters. Int J Chron Obstruct Pulmon Dis 2021;16:1101-7.
DOI: https://doi.org/10.2147/COPD.S302877
Ministry of Health, Hanoi Medical University, General Statistics Office of Viet Nam. Global Adult Tobacco Survey 2015. Accessed on: December 2021. Available from: https://extranet.who.int/ncdsmicrodata/index.php/catalog/875/study-description
Haughney J, Gruffydd-Jones K, Roberts J, et al. The distribution of COPD in UK general practice using the new GOLD classification. Eur Respir J 2014;43:993-1002.
DOI: https://doi.org/10.1183/09031936.00065013
Gedebjerg A, Szépligeti SK, Wackerhausen L-MH, et al. Prediction of mortality in patients with chronic obstructive pulmonary disease with the new Global Initiative for Chronic Obstructive Lung Disease 2017 classification: a cohort study. Lancet Respir Med 2018;6:204-12.
DOI: https://doi.org/10.1016/S2213-2600(18)30002-X
Yang Y, Li W, Guo Y, et al. Early COPD risk decision for adults aged from 40 to 79 years based on lung radiomics features. Front Med (Lausanne) 2022;9:845286.
DOI: https://doi.org/10.3389/fmed.2022.845286
Koarai A, Sugiura H, Yamada M, et al. Treatment with LABA versus LAMA for stable COPD: a systematic review and meta-analysis. BMC Pulm Med 2020;20:1-11.
DOI: https://doi.org/10.1186/s12890-020-1152-8
Koblizek V, Milenkovic B, Barczyk A, et al. Phenotypes of COPD patients with a smoking history in Central and Eastern Europe: the POPE Study. Eur Respir J 2017;49:1601446.
DOI: https://doi.org/10.1183/13993003.01446-2016
Vukoja M, Kopitovic I, Lazic Z, et al. Diagnosis and management of chronic obstructive pulmonary disease in Serbia: an expert group position statement. Int J Chron Obstruct Pulmon Dis 2019;14:1993-2002.
DOI: https://doi.org/10.2147/COPD.S214690
Han MK, Quibrera PM, Carretta EE, et al. Frequency of exacerbations in patients with chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort. Lancet Respir Med 2017;5:619-26.
DOI: https://doi.org/10.1016/S2213-2600(17)30207-2
McGarvey L, Lee AJ, Roberts J, et al. Characterisation of the frequent exacerbator phenotype in COPD patients in a large UK primary care population. Respir Med 2015;109:228-37.
DOI: https://doi.org/10.1016/j.rmed.2014.12.006
Ethics Approval
The study was approved by the Ethics Committee of the University of Medicine and Pharmacy at Ho Chi Minh city. The data collection process was permitted by the Department of Science and Training of the University Medical CenterHow to Cite
Nguyen-Nhu, Vinh, Lam-Phuoc Nguyen, Sy Duong-Quy, Pham Le An, and Tri Bui-Minh. 2023. “Classification of COPD As ABCD According to GOLD 2011 and 2017 Versions in COPD Patients at University Medical Center in Ho Chi Minh City, Vietnam”. Monaldi Archives for Chest Disease, July. https://doi.org/10.4081/monaldi.2023.2619.
Copyright (c) 2023 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
